VIDEO: EMPEROR-Preserved data show improved quality of life in HFpEF with empagliflozin
Javed Butler, MD, spoke with Healio about results from the EMPEROR-Preserved trial that he presented at the American Heart Association Scientific Sessions.
“We don’t really have contemporary data on quality of life improvement in patients with HF [with preserved ejection fraction] with pharmacologic therapy,” Butler, the Patrick H. Lehan Chair in Cardiovascular Research and professor and chairman of the department of medicine at the University of Mississippi Medical Center, said during a presentation.
Butler noted that most patients in the study had Kansas City Cardiomyopathy Questionnaire (KCCQ) at 70 points or higher — indicating that they were not a “very sick patient population,” but researchers found that there was improvement in any measure of KCCQ scores — total symptom score, overall summary score or clinical summary score — at any time point set in the study — 3, 8 or 12 months — and at any set threshold to measure improvement — 5, 10 and 15 points.
He said these measures were all in favor “of benefit with empagliflozin, and chances of worsening with placebo.”
The researchers also examined whether high KCCQ scores at baseline affect the clinical benefit of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), which was defined as CV mortality or HF hospitalization. Butler noted that the researchers found that “whether the scores were in the lowest tertile of KCCQ, intermediate tertile of KCCQ, or [the highest] tertile of KCCQ, all of those patients benefited with empagliflozin in terms of the clinical outcomes.
References:
Butler J, et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection: The EMPEROR-Preserved Trial. Presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).
Butler J, et al. Circulation. 2021;doi:10.1161/CIRCULATIONAHA.121.057812.
Collapse